Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025BloodOpen Access

Renal response of selinexor,  bortezomib, pomalidomide, and dexamethasone in newly diagnosed multiple myeloma patients with renal impairment: A phase 2, prospective, multicenter study

View Full Paper
Ask AI
Bookmark
Share

Authors

HZHuixing ZhouJMJie MaXQXiaoqi Qin

Discussion

Loading...

Member takes

Overview

Phase 2 study reports improved renal outcomes with SPVD in newly diagnosed multiple myeloma patients with renal dysfunction, indicating promising safety and efficacy.

Key Points

  • This research aims to evaluate the efficacy and safety of selinexor, pomalidomide, bortezomib, and dexamethasone (SPVD) in treating patients with newly diagnosed multiple myeloma and renal impairment.
  • Phase 2, multicenter study involving patients with renal impairment defined by creatinine clearance
  • Patients received SPVD treatment with specified dosing cycles for evaluation of renal response
  • Primary endpoint assessed was the renal overall response rate at 3 months along with secondary endpoints including hematological response and safety.
  • Renal overall response rate at 3 months was 87.3% with notable rates for complete and partial responses
  • 93.6% hematological overall response rate was observed, demonstrating substantial patient benefit
  • Adverse events included myelosuppression and infection, with manageable safety profile.

Cite This Study

Zhou et al. (2025) studied this question.

synapsesocial.com/papers/693624d74fa91c937236d178https://doi.org/10.1182/blood-2025-5830
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Safety and efficacy of first-line selinexor plus bortezomib, lenalidomide and dexamethasone (XVRd) in high risk newly diagnosed multiple myeloma: A multi-center, single-arm, phase ib/II trial2025
  2. 2The SCOPE trial: A phase 2 Study of selinexor in combination with pomalidomide and dexamethasone for patients with relapsed and/or refractory multiple myeloma2025
  3. 3Efficacy and safety of selinexor combined with VRD in newly diagnosed multiple myeloma with EMD: a phase 2 trial2026 · 2 citations
  4. 4Updated survival outcomes of pomalidomide/bortezomib/dexamethasone in newly diagnosed multiple myeloma with renal impairment: A prospective, open-label, multicenter, phase 2 study2025
  5. 5A novel conditioning regimen combining selinexor with melphalan Improves Survival in Patients with multiple myeloma:a prospective study2025